Thibaudeau C, Bour C, Scarpi-Luttenauer M, Mesdom P, Karges J, Gandioso A, Zhou L, Harlepp S, Detappe A, Burgy M, Martin S, Mellitzer G, Gaiddon C, Gasser G, Jung AC

J Med Chem. 2025 11 19;:

Nuclear factor E2 p45-related factor (NRF2) and peroxiredoxin 6 tissular expression as prognostic biomarkers for advanced HPV-negative squamous cell carcinoma of the oropharynx.

Philouze P, Benzerdjeb N, Malésys C, Wozny AS, Soumboundou M, Kobler A, Jung AC, Burgy M, Céruse P, Alphonse G, Rodriguez-Lafrasse C

Transl Oncol. 2025 11 3;63:102595

Impact of the thyroid hormone T3 and its nuclear receptor TRα1 on colon cancer stem cell phenotypes and response to chemotherapies.

Giolito MV, Bodoirat S, La Rosa T, Reslinger M, Guardia GDA, Mourtada J, Claret L, Joung A, Galante PAF, Penalva LOF, Plateroti M

Cell Death Dis. 2024 05 1;15(5):306

[The 14th Afipp scientific days].

Bressollette-Bodin C, Touzé A, Jung A, Herfs M, Lepiller Q, Bravo I, Péré H, Clavel C

Virologie (Montrouge). 2024 02 1;28(1):44-54

The Multifaceted Role of Human Dickkopf-3 (DKK-3) in Development, Immune Modulation and Cancer.

Mourtada J, Thibaudeau C, Wasylyk B, Jung AC

Cells. 2023 12 29;13(1):

Dynamic profiling of immune microenvironment during anti-PD-1 immunotherapy for head and neck squamous cell carcinoma: the IPRICE study.

Hélène C, Conrad O, Pflumio C, Borel C, Voegelin M, Bernard A, Schultz P, Onea MA, Jung A, Martin S, Burgy M

BMC Cancer. 2023 12 8;23(1):1209

A novel ΔNp63-dependent immune mechanism improves prognosis of HPV-related head and neck cancer.

Mourtada J, Lony C, Nicol A, De Azevedo J, Bour C, Macabre C, Roncarati P, Ledrappier S, Schultz P, Borel C, Burgy M, Wasylyk B, Mellitzer G, Herfs M, Gaiddon C, Jung AC

Front Immunol. 2023 10 25;14:1264093

Tumor-Suppressive and Immunomodulating Activity of miR-30a-3p and miR-30e-3p in HNSCC Cells and Tumoroids.

Conrad O, Burgy M, Foppolo S, Jehl A, Thiéry A, Guihard S, Vauchelles R, Jung AC, Mourtada J, Macabre C, Ledrappier S, Chenard MP, Onea MA, Danic A, Dourlhes T, Thibault C, Schultz P, Dontenwill M, Martin S

Int J Mol Sci. 2023 07 6;24(13):

A Novel Near-IR Absorbing Ruthenium(II) Complex as Photosensitizer for Photodynamic Therapy and its Cetuximab Bioconjugates.

Martínez-Alonso M, Gandioso A, Thibaudeau C, Qin X, Arnoux P, Demeubayeva N, Guérineau V, Frochot C, Jung AC, Gaiddon C, Gasser G

Chembiochem. 2023 04 5;:e202300203

Morpho-functional analysis of patient-derived xenografts reveals differential impact of gastric cancer and chemotherapy on the tumor ecosystem, affecting immune check point, metabolism, and sarcopenia.

Venkatasamy A, Guerin E, Reichardt W, Devignot V, Chenard MP, Miguet L, Romain B, Jung AC, Gross I, Gaiddon C, Mellitzer G

Gastric Cancer. 2022 12 19;:

The EXTREME Regimen Associating Cetuximab and Cisplatin Favors Head and Neck Cancer Cell Death and Immunogenicity with the Induction of an Anti-Cancer Immune Response.

De Azevedo J, Mourtada J, Bour C, Devignot V, Schultz P, Borel C, Pencreach E, Mellitzer G, Gaiddon C, Jung AC

Cells. 2022 09 14;11(18):

Antitumor Immune Response Triggered by Metal-Based Photosensitizers for Photodynamic Therapy: Where Are We?

Jung AC, Moinard-Butot F, Thibaudeau C, Gasser G, Gaiddon C

Pharmaceutics. 2021 Oct 26;13(11):

Ultrasound and Transcriptomics Identify a Differential Impact of Cisplatin and Histone Deacetylation on Tumor Structure and Microenvironment in a Patient-Derived In Vivo Model of Gastric Cancer.

Venkatasamy A, Guerin E, Blanchet A, Orvain C, Devignot V, Jung M, Jung AC, Chenard MP, Romain B, Gaiddon C, Mellitzer G

Pharmaceutics. 2021 Sep 16;13(9):

Bypassing the Resistance Mechanisms of the Tumor Ecosystem by Targeting the Endoplasmic Reticulum Stress Pathway Using Ruthenium- and Osmium-Based Organometallic Compounds: An Exciting Long-Term Collaboration with Dr. Michel Pfeffer.

Gaiddon C, Gross I, Meng X, Sidhoum M, Mellitzer G, Romain B, Delhorme JB, Venkatasamy A, Jung AC, Pfeffer M

Molecules. 2021 Sep 4;26(17):

Cav1/EREG/YAP Axis in the Treatment Resistance of Cav1-Expressing Head and Neck Squamous Cell Carcinoma.

Burgy M, Jehl A, Conrad O, Foppolo S, Bruban V, Etienne-Selloum N, Jung AC, Masson M, Macabre C, Ledrappier S, Burckel H, Mura C, Noël G, Borel C, Fasquelle F, Onea MA, Chenard MP, Thiéry A, Dontenwill M, Martin S

Cancers (Basel). 2021 Jun 18;13(12):

Novel Human Tenascin-C Function-Blocking Camel Single Domain Nanobodies.

Dhaouadi S, Ben Abderrazek R, Loustau T, Abou-Faycal C, Ksouri A, Erne W, Murdamoothoo D, Mörgelin M, Kungl A, Jung A, Ledrappier S, Benlasfar Z, Bichet S, Chiquet-Ehrismann R, Hendaoui I, Orend G, Bouhaouala-Zahar B

Front Immunol. 2021 ;12:635166

Weekly Paclitaxel, Carboplatin, and Cetuximab as First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma for Patients Ineligible to Cisplatin-Based Chemotherapy: A Retrospective Monocentric Study in 60 Patients.

Carinato H, Burgy M, Ferry R, Fischbach C, Kalish M, Guihard S, Brahimi Y, Flesch H, Bronner G, Schultz P, Frasie V, Thiéry A, Demarchi M, Petit T, Jung AC, Wagner P, Coliat P, Borel C

Front Oncol. 2021 ;11:714551

Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

Borel C, Jung AC, Burgy M

Cancers (Basel). 2020 Sep 21;12(9):

The Microenvironment of Head and Neck Cancers: Papillomavirus Involvement and Potential Impact of Immunomodulatory Treatments.

Outh-Gauer S, Morini A, Tartour E, Lépine C, Jung AC, Badoual C

Head Neck Pathol. 2020 Mar 2;:

HDAC4 Levels Control Sensibility toward Cisplatin in Gastric Cancer via the p53-p73/BIK Pathway.

Spaety ME, Gries A, Badie A, Venkatasamy A, Romain B, Orvain C, Yanagihara K, Okamoto K, Jung AC, Mellitzer G, Pfeffer S, Gaiddon C

Cancers (Basel). 2019 Nov 7;11(11):

Constitutive or Induced HIF-2 Addiction is Involved in Resistance to Anti-EGFR Treatment and Radiation Therapy in HNSCC.

Coliat P, Ramolu L, Jégu J, Gaiddon C, Jung AC, Pencreach E

Cancers (Basel). 2019 Oct 21;11(10):

Preferential Response of Basal-Like Head and Neck Squamous Cell Carcinoma Cell Lines to EGFR-Targeted Therapy Depending on -Driven Oncogenic Addiction.

Job S, Reyniès A, Heller B, Weiss A, Guérin E, Macabre C, Ledrappier S, Bour C, Wasylyk C, Etienne-Selloum N, Brino L, Gaiddon C, Wasylyk B, Jung AC

Cancers (Basel). 2019 Jun 8;11(6):

Comparative RNA sequencing reveals that HPV16 E6 abrogates the effect of E6*I on ROS metabolism.

Paget-Bailly P, Meznad K, Bruyère D, Perrard J, Herfs M, Jung AC, Mougin C, Prétet JL, Baguet A

Sci Rep. 2019 Apr 11;9(1):5938

Interest to consider re-challenging by cetuximab and platinum containing regimen in recurrent Head and Neck Cancer.

Borel C, Regnier-Gavier O, Carinato H, Guihard S, Antoni D, Demarchi M, Sirlin F, Exinger D, Petit-Jean E, Thiery A, Bronner G, Schultz P, Flesch H, Frasie V, Prébay D, Petit T, Jung AC, Burgy M, Coliat P

Oncotarget. 2018 Dec 25;9(101):37581-37588

A redox ruthenium compound directly targets PHD2 and inhibits the HIF1 pathway to reduce tumor angiogenesis independently of p53.

Vidimar V, Licona C, Camacho RC, Guerin E, Coliat P, Venkatasamy A, Ali M, Guenot D, Le Lagadec R, Jung AC, Freund JN, Pfeffer M, Mellitzer G, Sava G, Gaiddon C

Cancer Lett.. 2018 Oct 16;:

Primary, secondary and tertiary prevention of human papillomavirus-driven head and neck cancers.

Mirghani H, Jung AC, Fakhry C

Eur. J. Cancer. 2017 06;78:105-115

MiR-422a promotes loco-regional recurrence by targeting NT5E/CD73 in head and neck squamous cell carcinoma.

Bonnin N, Armandy E, Carras J, Ferrandon S, Battiston-Montagne P, Aubry M, Guihard S, Meyronet D, Foy JP, Saintigny P, Ledrappier S, Jung A, Rimokh R, Rodriguez-Lafrasse C, Poncet D

Oncotarget. 2016 Jul;7(28):44023-44038